Wat is de prijs voor EQRx, Inc. (EQRX)

Het prijs van EQRx, Inc. (EQRX) is $2.34

Wat is de marktkapitalisatie voor EQRx, Inc. (EQRX)

Marktkapitalisatie voorEQRx, Inc. (EQRX) is $728.90M

EQRx, Inc. (EQRX) K/O-verhouding

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Jaar	P/S-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/S-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/S-ratio	Verschil in P/S-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

P/S-ratio

Verschil in P/S-ratio

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

10.17

Argenx SE

ARGX.US

10.13

CSL Limited

CSL.AX

2.95

Moderna, Inc.

MRNA.US

11.28

Lonza Group AG

LONN.SW

EQRx, Inc.

EQRX

Categorie